EICHORCondition: Histologically or Cytologically Confirmed Advanced Solid Tumors · Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
an open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of SIM0532 in participants with advanced solid tumors. The study commences with a dose-escalation part (Part 1), followed by a dose-expansion part (Part 2).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of University of Science and Technology of China | Hefei, Anhui, China | — |
| The First Hospital of China Medical University | Shenyang, Liaoning, China | — |
| Shandong Cancer Hospital and Institute | Jinan, Shandong, China | — |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | — |
| Shanghai Pulmonary Hospital | Shanghai, Shanghai Municipality, China | — |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07749703